Lantern Pharma (LTRN) Common Equity (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Common Equity came in at $3.4 million in Q1 2026, down 79.46% YoY from $16.8 million in Q1 2025, and down 47.27% on a QoQ basis from $6.5 million in Q4 2025.
Lantern Pharma (LTRN) Common Equity (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Common Equity data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Common Equity fell 79.46% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 79.46% YoY) and the FY2025 annual result came in at $6.5 million, down 69.16% from the prior year.
- Common Equity slipped to $3.4 million in Q1 2026, from $6.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $65.3 million in Q1 2022 to a low of $3.4 million in Q1 2026.
- A 5-year average of $34.8 million and a median of $35.8 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity retreated 19.51% — and 2026, when it tumbled 79.46%.
- Tracing LTRN's Common Equity over 5 years: stood at $56.0 million in 2022, then retreated by 27.0% to $40.9 million in 2023, then plunged by 48.21% to $21.2 million in 2024, then plunged by 69.16% to $6.5 million in 2025, then sank by 47.27% to $3.4 million in 2026.
- The last three Common Equity figures came in at $3.4 million (Q1 2026), $6.5 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 3.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.45 Mn |
| Dec 31, 2025 | 6.53 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Jun 30, 2025 | 12.52 Mn |
| Mar 31, 2025 | 16.78 Mn |
| Dec 31, 2024 | 21.19 Mn |
| Sep 30, 2024 | 26.60 Mn |
| Jun 30, 2024 | 30.93 Mn |
| Mar 31, 2024 | 35.77 Mn |
| Dec 31, 2023 | 40.91 Mn |
| Sep 30, 2023 | 45.41 Mn |
| Jun 30, 2023 | 48.26 Mn |
| Mar 31, 2023 | 52.58 Mn |
| Dec 31, 2022 | 56.04 Mn |
| Sep 30, 2022 | 59.03 Mn |
| Jun 30, 2022 | 61.08 Mn |
| Mar 31, 2022 | 65.32 Mn |
| Dec 31, 2021 | 71.57 Mn |
| Sep 30, 2021 | 75.73 Mn |
| Jun 30, 2021 | 79.61 Mn |